Volume 23, Supplement—December 2017
Global Health Security Supplement
Capacity Development through the US President’s Malaria Initiative–Supported Antimalarial Resistance Monitoring in Africa Network
|Gene||Chromosome||Type of mutation||Antimalarial drug(s) associated with resistance|
||Polymorphism||Amodiaquine, chloroquine, lumefantrine, quinine|
|Change in copy number
|Propeller domain of kelch
||Artemisinin derivatives (e.g., artesunate)
|plasmepsin 2 and 3||14||Change in copy number||Piperaquine|
*Markers are selected based on the needs and priorities of each country’s malaria control program. This list will be expanded as additional molecular markers are identified.
Page created: November 20, 2017
Page updated: November 20, 2017
Page reviewed: November 20, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.